
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1588617/publications.pdf Version: 2024-02-01



AMANDA MOCDOFT

#	Article	IF	CITATIONS
1	Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps. HIV Medicine, 2022, 23, 48-59.	1.0	7
2	The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. Aids, 2022, 36, 423-435.	1.0	8
3	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV Medicine, 2022, 23, 585-598.	1.0	2
4	HCV reinfection after HCV therapy among HIV/HCVâ€coinfected individuals in Europe. HIV Medicine, 2022, 23, 684-692.	1.0	4
5	Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark. Journal of Viral Hepatitis, 2022, 29, 727-736.	1.0	3
6	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	1.9	6
7	Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1690-1698.	1.9	10
8	Healthcare delivery for HIVâ€positive people with tuberculosis in Europe. HIV Medicine, 2021, 22, 283-293.	1.0	6
9	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 248-257.	0.9	3
10	Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. Frontiers in Immunology, 2021, 12, 668113.	2.2	7
11	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. Aids, 2021, 35, 2025-2033.	1.0	4
12	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100Âcells/µL. Journal of the International AIDS Society, 2021, 24, e25726.	1.2	8
13	Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	2.0	14
14	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
15	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study. BMC Infectious Diseases, 2021, 21, 1038.	1.3	9
16	Clinical outcomes in persons coinfected with HIV and HCV: Impact of HCV treatment. Clinical Infectious Diseases, 2020, 70, 2131-2140.	2.9	9
17	The EuroSIDA study: 25 years of scientific achievements. HIV Medicine, 2020, 21, 71-83.	1.0	24
18	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. Journal of Infectious Diseases, 2020, 222, 1353-1362.	1.9	17

#	Article	IF	CITATIONS
19	Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR. Kidney International Reports, 2020, 5, 734-737.	0.4	2
20	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviralâ€naÃ⁻ve persons starting treatment. HIV Medicine, 2020, 21, 599-606.	1.0	9
21	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	0.9	24
22	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
23	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infectious Diseases, 2020, 7, ofaa470.	0.4	1
24	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657.	2.9	21
25	Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. BMC Infectious Diseases, 2019, 19, 708.	1.3	9
26	Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the Copenhagen Comorbidity in HIV Infection (COCOMO) study*. HIV Medicine, 2019, 20, 639-647.	1.0	7
27	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	1.9	8
28	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz215.	0.4	21
29	Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2019, 221, 419-427.	1.9	12
30	Establishing a hepatitis C continuum of care among <scp>HIV</scp> /hepatitis C virus oinfected individuals in Euro <scp>SIDA</scp> . HIV Medicine, 2019, 20, 264-273.	1.0	9
31	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. PLoS ONE, 2019, 14, e0209911.	1.1	19
32	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. Aids, 2019, 33, 2013-2024.	1.0	13
33	Serious clinical events in HIV-positive persons with chronic kidney disease. Aids, 2019, 33, 2173-2188.	1.0	7
34	Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. Aids, 2019, 33, 675-683.	1.0	34
35	Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. Clinical Infectious Diseases, 2018. 67. 579-586.	2.9	73
36	Longâ€ŧerm effectiveness of recommended boosted protease inhibitorâ€based antiretroviral therapy in Europe. HIV Medicine, 2018, 19, 324-338.	1.0	4

#	Article	IF	CITATIONS
37	Airflow limitation in people living with HIV and matched uninfected controls. Thorax, 2018, 73, 431-438.	2.7	57
38	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Medicine, 2018, 19, 252-260.	1.0	2
39	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	3.0	12
40	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study. Antiviral Therapy, 2018, 23, 405-413.	0.6	5
41	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	1.7	16
42	Incidence of cancer and overall risk of mortality in individuals treated with raltegravirâ€based and nonâ€raltegravirâ€based combination antiretroviral therapy regimens. HIV Medicine, 2018, 19, 102-117.	1.0	6
43	The extent of Bâ€cell activation and dysfunction preceding lymphoma development in <scp>HIV</scp> â€positive people. HIV Medicine, 2018, 19, 90-101.	1.0	14
44	Contemporary protease inhibitors and cardiovascular risk. Current Opinion in Infectious Diseases, 2018, 31, 8-13.	1.3	28
45	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. Aids, 2018, 32, 205-215.	1.0	5
46	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. Transplantation Direct, 2018, 4, e355.	0.8	12
47	Classification of death causes after transplantation (CLASS). Medicine (United States), 2018, 97, e11564.	0.4	14
48	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. Aids, 2018, 32, 2807-2819.	1.0	13
49	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. Aids, 2018, 32, 1995-2004.	1.0	24
50	Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. Aids, 2018, 32, 2405-2416.	1.0	83
51	Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. BMC Infectious Diseases, 2018, 18, 191.	1.3	5
52	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Eurosurveillance, 2018, 23, .	3.9	12
53	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	0.9	22
54	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. Aids, 2017, 31, 1261-1270.	1.0	16

#	Article	IF	CITATIONS
55	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases, 2017, 64, 1413-1421.	2.9	66
56	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International Journal of Antimicrobial Agents, 2017, 50, 453-460.	1.1	19
57	Higher rates of tripleâ€class virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
58	Reference curves for <scp>CD</scp> 4 Tâ€cell count response to combination antiretroviral therapy in <scp>HIV</scp> â€lâ€infected treatmentâ€naÃ⁻ve patients. HIV Medicine, 2017, 18, 33-44.	1.0	16
59	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	3.9	17
60	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	1.0	50
61	European <scp>AIDS</scp> Clinical Society Standard of Care meeting on <scp>HIV</scp> and related coinfections: The Rome Statements. HIV Medicine, 2016, 17, 445-452.	1.0	8
62	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	1.0	10
63	Associations between HIV-RNA-based indicators and virological and clinical outcomes. Aids, 2016, 30, 1961-1972.	1.0	10
64	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.4	20
65	Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. Current HIV/AIDS Reports, 2016, 13, 149-157.	1.1	36
66	The benefits and risks of PrEP and kidney function. Lancet HIV,the, 2016, 3, e501-e502.	2.1	1
67	Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. Antiviral Therapy, 2016, 21, 529-534.	0.6	8
68	Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. BMC Infectious Diseases, 2016, 16, 335.	1.3	15
69	The cardiovascular risk management for people living with HIV in Europe. Aids, 2016, 30, 2505-2518.	1.0	27
70	Infectionâ€related and â€unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600.	1.0	37
71	MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year. Scandinavian Journal of Gastroenterology, 2016, 51, 1360-1366.	0.6	12
72	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus–coinfected Individuals From 2001 to 2014: A Multicohort Study. Clinical Infectious Diseases, 2016, 63, 821-829.	2.9	48

#	Article	IF	CITATIONS
73	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV,the, 2016, 3, e120-e131.	2.1	53
74	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV,the, 2016, 3, e23-e32.	2.1	157
75	Thrombocytopenia and cancer risk during HIV infection. Aids, 2015, 29, 1425-1427.	1.0	Ο
76	Major differences in organization and availability of health care and medicines for <scp>HIV/TB</scp> coinfected patients across <scp>E</scp> urope. HIV Medicine, 2015, 16, 544-552.	1.0	19
77	Liver-related death among HIV/hepatitis C virus-co-infected individuals. Aids, 2015, 29, 1205-1215.	1.0	46
78	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS ONE, 2015, 10, e0145380.	1.1	19
79	Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections. EBioMedicine, 2015, 2, 699-705.	2.7	18
80	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	3.9	119
81	Hepatitis C seroconversions in <scp>HIV</scp> infection across Europe: which regions and patient groups are affected?. Liver International, 2015, 35, 2384-2391.	1.9	33
82	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Aids, 2015, 29, 193-200.	1.0	13
83	Kidney disease in antiretroviralâ€naÃ⁻ve <scp>HIV</scp> â€positive adults with high <scp>CD</scp> 4 counts: prevalence and predictors of kidney disease at enrolment in the <scp>INSIGHT S</scp> trategic <scp>T</scp> iming of <scp>A</scp> nti <scp>R</scp> etroviral <scp>T</scp> reatment (<scp>START</scp>) trial. HIV Medicine, 2015, 16, 55-63.	1.0	22
84	Changing utilization of Stavudine (d4T) in HIVâ€positive people in 2006–2013 in the EuroSIDA study. HIV Medicine, 2015, 16, 533-543.	1.0	11
85	Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. PLoS ONE, 2015, 10, e0140845.	1.1	43
86	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
87	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. Journal of the International AIDS Society, 2014, 17, 19561.	1.2	1
88	602Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. Open Forum Infectious Diseases, 2014, 1, S26-S26.	0.4	0
89	HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC Infectious Diseases, 2014, 14, S13.	1.3	19
90	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. Journal of Infectious Diseases, 2014, 210, 234-243.	1.9	42

#	Article	IF	CITATIONS
91	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. European Respiratory Journal, 2014, 43, 166-177.	3.1	30
92	Late presentation to <scp>HIV</scp> / <scp>AIDS</scp> testing, treatment or continued care: clarifying the use of <scp>CD4</scp> evaluation in the consensus definition. HIV Medicine, 2014, 15, 129-129.	1.0	3
93	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	0.9	64
94	Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. Current Opinion in HIV and AIDS, 2014, 9, 41-47.	1.5	16
95	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. Aids, 2014, 28, 2565-2571.	1.0	9
96	Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. Journal of Infection, 2014, 68, 259-263.	1.7	38
97	A comparison of estimated glomerular filtration rates using <scp>C</scp> ockcroftâ^' <scp>G</scp> ault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in <scp>HIV</scp> infection. HIV Medicine, 2014, 15, 144-152.	1.0	23
98	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
99	High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. HIV Medicine, 2014, 15, n/a-n/a.	1.0	4
100	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection, 2014, 42, 757-762.	2.3	4
101	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrology, 2014, 15, 51.	0.8	10
102	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 2014, 59, 287-297.	2.9	136
103	Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. Journal of Clinical Virology, 2014, 60, 295-300.	1.6	22
104	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. Aids, 2014, 28, 187-199.	1.0	60
105	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. Aids, 2014, 28, 577-587.	1.0	11
106	Deteriorating renal function and clinical outcomes in HIV-positive persons. Aids, 2014, 28, 727-737.	1.0	25
107	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE, 2014, 9, e87160.	1.1	35
108	Severe bacterial non-aids infections in HIV-positive persons: Incidence rates and risk factors. Journal of Infection, 2013, 66, 439-446.	1.7	43

#	Article	IF	CITATIONS
109	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. Journal of Hepatology, 2013, 59, 213-220.	1.8	41
110	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Aids, 2013, 27, 907-918.	1.0	12
111	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. Aids, 2013, 27, 1641-1655.	1.0	11
112	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. BioMed Research International, 2013, 2013, 1-9.	0.9	10
113	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
114	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya. Journal of Infectious Diseases, 2013, 207, 1359-1369.	1.9	271
115	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
116	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
117	Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Medicine, 2013, 14, 614-623.	1.0	46
118	Advanced chronic kidney disease, endâ€stage renal disease and renal death among <scp>HIV</scp> â€positive individuals in <scp>E</scp> urope. HIV Medicine, 2013, 14, 503-508.	1.0	34
119	Stability of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) <scp>RNA</scp> levels among interferonâ€naÃ⁻ve <scp>HIV</scp> / <scp>HCV</scp> â€coinfected individuals treated with combination antiretroviral therapy. HIV Medicine, 2013, 14, 370-378.	1.0	16
120	An internationally generalizable risk index for mortality after one year of antiretroviral therapy. Aids, 2013, 27, 563-572.	1.0	170
121	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS ONE, 2013, 8, e64283.	1.1	25
122	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq0 C	00 ₁ gBT /C	Overlock 10 Tf
123	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationÁ. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
124	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323.	1.0	35
125	The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression. Antiviral Therapy, 2012, 17, 1291-1300.	0.6	10
126	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.	1.0	62

8

Aids, 2012, 26, 1917-1926.

#	Article	IF	CITATIONS
127	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
128	Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infectious Diseases, 2012, 12, 229.	1.3	9
129	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. PLoS ONE, 2012, 7, e41673.	1.1	32
130	Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE, 2012, 7, e40245.	1.1	66
131	HIV Therapies and the Kidney: Some Good, Some Not So Good?. Current HIV/AIDS Reports, 2012, 9, 111-120.	1.1	14
132	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
133	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Aids, 2011, 25, 1305-1315.	1.0	157
134	Tuberculosis among HIV-positive patients across Europe. Aids, 2011, 25, 1505-1513.	1.0	19
135	The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523.	1.2	129
136	Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. Aids, 2011, 25, 2259-2268.	1.0	51
137	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. HIV Clinical Trials, 2011, 12, 109-117.	2.0	29
138	HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood, 2011, 117, 6100-6108.	0.6	99
139	Haemoglobin and Anaemia in the Smart Study. Antiviral Therapy, 2011, 16, 329-337.	0.6	12
140	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. Antiviral Therapy, 2011, 16, 667-675.	0.6	16
141	The difficulties of classifying renal disease in HIV-infected patients*. HIV Medicine, 2011, 12, 1-3.	1.0	15
142	Late presentation of HIV infection: a consensus definition. HIV Medicine, 2011, 12, 61-64.	1.0	378
143	A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine, 2011, 12, 259-268.	1.0	19
144	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42

#	Article	IF	CITATIONS
145	Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 582-589.	0.9	42
146	Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption. Aids, 2010, 24, 857-865.	1.0	59
147	Biomarkers of impaired renal function. Current Opinion in HIV and AIDS, 2010, 5, 524-530.	1.5	38
148	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 2010, 15, 563-570.	0.6	12
149	Medical and Societal Consequences of Late Presentation. Antiviral Therapy, 2010, 15, 9-15.	0.6	61
150	Relationship between current level of immunodeficiency and nonâ€acquired immunodeficiency syndromeâ€defining malignancies. Cancer, 2010, 116, 5306-5315.	2.0	120
151	A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study. Journal of the International AIDS Society, 2010, 13, O16.	1.2	0
152	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Journal of the International AIDS Society, 2010, 13, O43.	1.2	2
153	Haemoglobin and anaemia in the SMART study. Journal of the International AIDS Society, 2010, 13, P144.	1.2	0
154	Changing antiretrovirals whilst viral load <50 copies/ml and relationship with CD4 count changes. Journal of the International AIDS Society, 2010, 13, P24.	1.2	0
155	Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA. Journal of the International AIDS Society, 2010, 13, P82.	1.2	0
156	Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIVâ€lâ€infected patients treated with abacavir. HIV Medicine, 2010, 11, 200-208.	1.0	13
157	History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change [*] . HIV Medicine, 2010, 11, 469-478.	1.0	23
158	Is It Safe to Discontinue Primary <i>Pneumocystis jiroveci</i> Pneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL?. Clinical Infectious Diseases, 2010, 51, 611-619.	2.9	96
159	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Journal of Antimicrobial Chemotherapy, 2010, 65, 548-555.	1.3	51
160	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids, 2010, 24, 697-706.	1.0	150
161	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids, 2010, 24, 1667-1678.	1.0	353
162	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 262-270.	0.9	243

#	Article	IF	CITATIONS
163	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
164	Use of Risk Equations for Predicting Disease Progression in HIV Infection. Clinical Infectious Diseases, 2009, 48, 951-953.	2.9	4
165	Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Aids, 2009, 23, 71-82.	1.0	47
166	Variable Impact on Mortality of AIDSâ€Đefining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDSâ€Đefining Conditions Are Created Equal. Clinical Infectious Diseases, 2009, 48, 1138-1151.	2.9	108
167	Reply to Pascual Pareja et al Journal of Infectious Diseases, 2009, 199, 1557-1557.	1.9	1
168	Analysis of the incidence and mortality of vulval cancer in women in South East England 1960–1999. Archives of Gynecology and Obstetrics, 2009, 279, 113-117.	0.8	8
169	411 HEPATITIS C VIRUS REAPPEARANCE IN HIV-INFECTED PATIENTS WITH SPONTANEOUS HCV-RNA CLEARANCE. Journal of Hepatology, 2009, 50, S155.	1.8	1
170	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Aids, 2009, 23, 2199-2208.	1.0	40
171	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Aids, 2009, 23, 2485-2495.	1.0	36
172	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 357-363.	0.9	26
173	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Aids, 2009, 23, 1689-1699.	1.0	69
174	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. Antiviral Therapy, 2009, 14, 1065-1074.	0.6	92
175	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Aids, 2009, 23, 2029-2037.	1.0	64
176	Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 457-463.	0.9	49
177	Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Medicine, 2008, 9, 41-46.	1.0	9
178	Loss to followâ€up in an international, multicentre observational study. HIV Medicine, 2008, 9, 261-269.	1.0	91
179	Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/µl in the era of cART. Scandinavian Journal of Infectious Diseases, 2008, 40, 908-913.	1.5	2
180	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Aids, 2008, 22, 2187-2198.	1.0	37

#	Article	IF	CITATIONS
181	Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. Aids, 2008, 22, 997-998.	1.0	6
182	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 324-333.	0.9	46
183	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clinical Infectious Diseases, 2008, 47, 1468-1475.	2.9	53
184	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIVâ€Infected Patients with Antiâ€HCV Antibodies in Europe. Journal of Infectious Diseases, 2008, 198, 1337-1344.	1.9	145
185	The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. Aids, 2008, 22, 47-56.	1.0	38
186	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids, 2008, 22, 367-376.	1.0	43
187	Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. Aids, 2008, 22, 2381-2390.	1.0	30
188	The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results. Central European Journal of Public Health, 2008, 16, 99-105.	0.4	15
189	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 2008, 13, 959-67.	0.6	50
190	Incidence of abacavir hypersensitivity reactions in EuroSIDA. Antiviral Therapy, 2008, 13, 687-696.	0.6	14
191	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy, 2008, 13, 959-967.	0.6	65
192	Current Hemoglobin Levels Are More Predictive of Disease Progression Than Hemoglobin Measured at Baseline in Patients Receiving Antiretroviral Treatment for HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2007, 23, 1183-1188.	0.5	16
193	Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. Clinical Infectious Diseases, 2007, 45, 1518-1521.	2.9	98
194	Clinical outcomes in clinical trials of anti-HIV treatment. Future HIV Therapy, 2007, 1, 251-258.	0.5	1
195	Chronic renal failure among HIV-1-infected patients. Aids, 2007, 21, 1119-1127.	1.0	192
196	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. Aids, 2007, 21, 1867-1875.	1.0	38
197	Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet, The, 2007, 370, 407-413.	6.3	217
198	Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine, 2007, 8, 96-104.	1.0	68

#	Article	IF	CITATIONS
199	Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antiviral Therapy, 2007, 12, 325-33.	0.6	6
200	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 ⁺ T-cell Counts. Antiviral Therapy, 2007, 12, 325-334.	0.6	35
201	Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor–Containing cART Regimens in Antiretroviral-NaÃ`ve Patients Starting cART After January 1, 2000. HIV Clinical Trials, 2006, 7, 271-284.	2.0	6
202	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Aids, 2006, 20, 1141-1150.	1.0	39
203	Changes in AIDS-Defining Illnesses in a London Clinic, 1987???1998. Journal of Acquired Immune Deficiency Syndromes, 2006, 21, 401.	0.3	10
204	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 229-237.	0.9	40
205	Factors Associated with the Development of Opportunistic Infections in HIVâ€1–Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. Journal of Infectious Diseases, 2006, 194, 633-641.	1.9	70
206	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scandinavian Journal of Infectious Diseases, 2006, 38, 1092-1097.	1.5	15
207	The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials, 2006, 3, 119-132.	0.7	8
208	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. Antiviral Therapy, 2006, 11, 707-716.	0.6	52
209	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2005, 21, 527-536.	0.5	36
210	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2005, 21, 743-752.	0.5	69
211	Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV. American Journal of Gastroenterology, 2005, 100, 1446-1454.	0.2	29
212	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids, 2005, 19, 593-601.	1.0	472
213	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. Aids, 2005, 19, 2117-2125.	1.0	109
214	Age related trends in the incidence of endometrial cancer in South East England 1962 – 1997. Journal of Obstetrics and Gynaecology, 2005, 25, 35-38.	0.4	14
215	Influence of Hepatitis C Virus Infection on HIVâ€1 Disease Progression and Response to Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 192, 992-1002.	1.9	362
216	Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. Antiviral Therapy, 2005, 10, 779-90.	0.6	5

#	Article	IF	CITATIONS
217	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. Antiviral Therapy, 2005, 10, 779-790.	0.6	22
218	Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIVâ€l–Infected Adults: A EuroSIDA Study. Journal of Infectious Diseases, 2004, 190, 148-155.	1.9	58
219	Starting highly active antiretroviral therapy: why, when and response to HAART. Journal of Antimicrobial Chemotherapy, 2004, 54, 10-13.	1.3	28
220	Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group. Journal of Infectious Diseases, 2004, 190, 1947-1956.	1.9	80
221	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Medicine, 2004, 5, 437-447.	1.0	52
222	Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994?2001. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 550-9.	1.3	62
223	Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of Neurology, 2004, 55, 320-328.	2.8	273
224	The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. Cancer, 2004, 100, 2644-2654.	2.0	132
225	Causes of death in HIV infection. Aids, 2004, 18, 2333-2337.	1.0	34
226	HIV Survival Benefit Associated with Earlier Antiviral Therapy. Annals of Internal Medicine, 2004, 140, 578.	2.0	7
227	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study. Antiviral Therapy, 2004, 9, 787-800.	0.6	7
228	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, The, 2003, 362, 22-29.	6.3	1,157
229	Continuation of hormone replacement therapy after hysterectomy. Climacteric, 2003, 6, 58-66.	1.1	1
230	Anemia and Survival in Human Immunodeficiency Virus. Clinical Infectious Diseases, 2003, 37, S297-S303.	2.9	46
231	Virological rebound after suppression on highly active antiretroviral therapy. Aids, 2003, 17, 1741-1751.	1.0	99
232	Continuation of hormone replacement therapy after hysterectomy. Climacteric, 2003, 6, 58-66.	1.1	0
233	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell Counts. Journal of Infectious Diseases, 2002, 186, 189-197.	1.9	52
234	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. Journal of Infectious Diseases, 2002, 185, 178-187.	1.9	116

#	Article	IF	CITATIONS
235	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 58-61.	0.9	9
236	Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. Aids, 2002, 16, 1663-1671.	1.0	259
237	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 58-61.	0.9	15
238	Highly active antiretroviral therapy and cervical intraepithelial neoplasia. Aids, 2002, 16, 927-929.	1.0	36
239	Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antiviral Therapy, 2002, 7, 21-30.	0.6	27
240	Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet, The, 2001, 357, 592-598.	6.3	403
241	Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. Aids, 2001, 15, 1261-1268.	1.0	286
242	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. Aids, 2001, 15, 999-1008.	1.0	8
243	Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART. HIV Clinical Trials, 2001, 2, 484-492.	2.0	66
244	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. Aids, 2001, 15, 201-209.	1.0	48
245	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 159-163.	0.9	58
246	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 159-163.	0.9	40
247	Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Medicine, 2001, 2, 52-58.	1.0	41
248	The surgical management of women with ovarian cancer in the south west of England. British Journal of Cancer, 2001, 85, 1824-1830.	2.9	64
249	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. Aids, 2001, 15, 185-194.	1.0	187
250	Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine, 2001, 344, 168-174.	13.9	155
251	Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus–Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study. Journal of Infectious Diseases, 2001, 183, 1290-1294.	1.9	219
252	Reduced bone mineral density in HIV-positive individuals. Aids, 2001, 15, 1731-1733.	1.0	107

#	Article	IF	CITATIONS
253	Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe. Archives of Internal Medicine, 2000, 160, 1123.	4.3	220
254	Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 475-482.	0.9	95
255	Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 475-482.	0.9	89
256	Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Aids, 2000, 14, 1545-1552.	1.0	79
257	Regional differences in presentation of AIDS in Europe. Epidemiology and Infection, 2000, 125, 143-151.	1.0	13
258	Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Medicine, 2000, 1, 212-218.	1.0	24
259	Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1094-1096.	1.1	10
260	Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Aids, 2000, 14, 1717-1720.	1.0	34
261	Infections withMycobacterium tuberculosisandMycobacterium aviumamong HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 865-872.	2.5	124
262	AIDS across Europe, 1994–98: the EuroSIDA study. Lancet, The, 2000, 356, 291-296.	6.3	431
263	Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antiviral Therapy, 2000, 5, 107-12.	0.6	5
264	Virological Failure among Patients on Haart from across Europe: Results from the Eurosida Study. Antiviral Therapy, 2000, 5, 107-112.	0.6	12
265	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. Aids, 1999, 13, 943-950.	1.0	335
266	Changes in AIDS-Defining Illnesses in a London Clinic, 1987–1998. Journal of Acquired Immune Deficiency Syndromes, 1999, 21, 401.	0.3	18
267	Does European or non-European origin influence health care and prognosis for HIV patients in Europe?. HIV Medicine, 1999, 1, 2-9.	1.0	14
268	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. HIV Medicine, 1999, 1, 32-39.	1.0	9
269	Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. , 1999, 58, 280-285.		17
270	Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet, The, 1999, 353, 1293-1298.	6.3	206

#	Article	IF	CITATIONS
271	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Aids, 1999, 13, 1255-1261.	1.0	46
272	Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. Aids, 1999, 13, 1203-1206.	1.0	93
273	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. Aids, 1999, 13, 2281-2288.	1.0	22
274	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 369.	0.9	45
275	Changes in AIDS-Defining Illnesses in a London Clinic, 1987–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 401.	0.9	52
276	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 369.	0.9	122
277	Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study. Annals of Internal Medicine, 1999, 130, 570.	2.0	157
278	Impact of Kaposi's sarcoma on HIV disease progression. Aids, 1999, 13, 286.	1.0	2
279	Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 401-7.	0.9	27
280	Cofactors and markers of disease progression in human immunodeficiency virus infection. Journal of the Royal Statistical Society Series A: Statistics in Society, 1998, 161, 177-189.	0.6	6
281	Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, The, 1998, 352, 1725-1730.	6.3	1,182
282	Changes in Lymphocyte Subsets in Human Immunodeficiency Virusâ€Positive Persons with <5 CD4 T Lymphocytes/mm ³ . Journal of Infectious Diseases, 1998, 178, 1166-1169.	1.9	1
283	The Incidence of AIDS-Defining Illnesses in 4883 Patients With Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 1998, 158, 491.	4.3	62
284	Changes in use of antiretroviral therapy in regions of Europe over time. Aids, 1998, 12, 2031-2039.	1.0	51
285	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. Aids, 1998, 12, 2161-2167.	1.0	142
286	A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. Aids, 1998, 12, 1155-1161.	1.0	11
287	Do women with HIV infection consult with their CPs?. British Journal of General Practice, 1998, 48, 1329-30.	0.7	4
288	Access to medical care one year prior to diagnosis in 100 HIV-positive women. Family Practice, 1997, 14, 255-257.	0.8	20

#	Article	IF	CITATIONS
289	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. International Journal of Epidemiology, 1997, 26, 400-407.	0.9	69
290	The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiology and Infection, 1997, 118, 259-266.	1.0	11
291	Survival after a very low (< 5 × 106/l) CD4+ T-cell count in individuals infected with HIV. Aids, 1997, 11, 1123-1127.	1.0	4
292	Cervical Abnormality and Sexually Transmitted Disease Screening in Human Immunodeficiency Virus-Positive Women. Obstetrics and Gynecology, 1997, 89, 71-75.	1.2	34
293	Cross-Sectional Studies in AIDS Pathogenesis. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 153-157.	0.3	1
294	CD8+, CD38+ Lymphocyte Percent. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 158-162.	0.3	111
295	Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. BMJ: British Medical Journal, 1997, 314, 409-409.	2.4	50
296	Increased number of primed activated CD8+CD38+CD45RO+T cells predict the decline of CD4+T cells in HIV-1-infected patients. Aids, 1996, 10, 827-834.	1.0	168
297	Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men. Aids, 1996, 10, 344.	1.0	71
298	Infertility among human immunodeficiency virus-positive women: incidence and treatment dilemmas. Human Reproduction, 1996, 11, 2793-2796.	0.4	20
299	Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Aids, 1996, 10, 1101-5.	1.0	97
300	The use of CD4 counts as prognostic markers in HIV infection. Aids, 1995, 9, 1205-1206.	1.0	1
301	Antiviral therapy. Nature, 1995, 375, 195-195.	13.7	24
302	Percentage of CD4 Lymphocytes and Risk of AIDS. JAMA - Journal of the American Medical Association, 1995, 274, 1836.	3.8	1
303	Serum HIV-1 RNA and routine patient monitoring. Lancet, The, 1995, 345, 1441-1442.	6.3	1
304	Active drug injecting and progression of HIV infection. Aids, 1994, 8, 385-386.	1.0	4
305	The surgical management of women with ovarian cancer in the south west of England. , 0, .		1